AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29964145
Drug: In-person consultation
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In-person consultation at public events (e.g., basketball game, county fair)
Trial: 29966800
Drug: Crizotinib 250
RxNorm normalized name: crizotinib 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crizotinib 250 mg orally twice daily continuously (3-week cycles)
Trial: 29966800
Drug: Chemotherapy (pemetrexed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (pemetrexed 500 mg/m2 intravenously)
Trial: 29966863
Drug: Lobaplatin 25-50
RxNorm normalized name: Lobaplatin
DrugBank: Lobaplatin (DB13049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lobaplatin 25-50 mg/m² concurrent with IMRT
Trial: 29967693
Drug: Schizophrenia Coping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schizophrenia Coping Oral Health Profile (SCOOHP)
Trial: 29968431
Drug: Atorvastatin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin plus pioglitazone (30 mg/day)
Trial: 29970005
Drug: Systematic medication
RxNorm normalized name: Integrase Inhibitors, antiinfectives for systematic use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic medication review based on the RASP list
Trial: 29970319
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg of soy-derived phosphatidic acid (PA)
Trial: 29970357
Drug: Mobile phone
RxNorm normalized name: Chamaemelum nobile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile phone delivered intervention based on Acceptance and Commitment Therapy (ACT)
Trial: 29970389
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) injections on days 0, 30, 60, and 90, plus hyaluronic acid five times per day
Trial: 29972089
Drug: Fluticasone furoate/vilanterol
RxNorm normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone furoate/vilanterol (FF/VI) 100[200]/25 µg
Trial: 29972716
Drug: ASP8273 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP8273 300 mg
Trial: 29973153
Drug: Phenylbutyrate (PBA)
DrugBank: Phenylbutyric acid (DB06819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylbutyrate (PBA) 500mg twice daily for 8 weeks
Trial: 29973204
Drug: Ipilimumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab (10 mg/kg IV every 3 weeks for 2 doses)
Trial: 29973256
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 25% silver nitrate (AgNO3)
Trial: 29975012
Drug: Patients without
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients without widespread pain (WP) receiving biologic or conventional synthetic disease-modifying antirheumatic drugs (DMARDs)
Trial: 29977205
Drug: Pharmacist-led intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led intervention to enhance medication adherence
Trial: 29977284
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of serum TFF3 and pepsinogen
Trial: 29978216
Drug: BIND-014 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIND-014 (60 mg/m2 intravenously on day 1 of 21-day cycles in combination with prednisone)
Trial: 29978298
Drug: Ultrasound-guided left
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided left lateral TAP block combined with RS block (15 ml of 0.5% ropivacaine for TAP and 10 ml of 0.5% ropivacaine for RS)
Trial: 29980242
Drug: Daily second-hand
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily second-hand tobacco smoke (SHS) exposure
Trial: 29980242
Drug: Daily second-hand
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily second-hand tobacco smoke (SHS) exposure among women
Trial: 29980242
Drug: Daily second-hand
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily second-hand tobacco smoke (SHS) exposure among men
Trial: 29980490
Drug: FOLFIRI +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI + Aflibercept (4 mg/kg body weight delivered intravenously every 2 weeks for a maximum of 12 cycles, followed by aflibercept maintenance)
Trial: 29980535
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg β3-AR agonist mirabegron
Trial: 29980535
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg β3-AR agonist mirabegron
Trial: 29980537
Drug: HDC/IL2 (histamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDC/IL2 (histamine dihydrochloride and low-dose interleukin-2)
Trial: 29980542
Drug: Selective CT
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective CT fluoroscopy transforaminal epidural steroid (arm 1)
Trial: 29980542
Drug: 15 days
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 days tapering dose of oral steroids (arm 3)
Trial: 29980542
Drug: Sham epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham epidural and oral placebo control (arm 4)
Trial: 29980894
Drug: AMG 900
RxNorm normalized name: AMG-900
DrugBank: AMG-900 (DB17197)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 900 at 40 mg/day with G-CSF
Trial: 29980907
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy and axillary dissection
Trial: 29981205
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + 1% MtF gel
Trial: 29981205
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + AV gel
Trial: 29982198
Drug: Daily perception
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily perception of fetal hiccups
Trial: 29982217
Drug: Oral propranolol-hydrochloride
RxNorm normalized name: Propranolol Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral propranolol-hydrochloride (1.6 mg/kg/day in three to four divided dosages) until discharge, for a maximum of 10 weeks.
Trial: 29982218
Drug: Azithromycin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (single oral dose at months 6, 9, 12, and 15)
Trial: 29982218
Drug: Nicotinamide (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinamide (daily oral dose given to mother for breastfeeding children aged 0-6 months and directly to children aged 6-18 months)
Trial: 29982449
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusions using flucloxacillin
Trial: 29982449
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusions using cefepime
Trial: 29982449
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusions using vancomycin
Trial: 29982449
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusions using piperacillin/tazobactam
Trial: 29982449
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusions
Trial: 29982514
Drug: Pivmecillinam 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivmecillinam 200 mg three times daily for ≤5 days
Trial: 29982514
Drug: Pivmecillinam 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivmecillinam 400 mg three times daily
Trial: 29983087
Drug: Veliparib (PARP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib (PARP inhibitor)
Trial: 30029855
Drug: Ivacaftor treatment
RxNorm normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ivacaftor treatment for 3 months
Trial: 29983992
Drug: Cognitive remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive remediation therapy (CRT) + Teach the Parent
Trial: 29983992
Drug: Cognitive remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive remediation therapy (CRT) + contact control (Family Fun Time)
Trial: 29984044
Drug: Ozone therapy
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone therapy as an adjunct to sterile saline
Trial: 29984608
Drug: Overused drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overused drug withdrawal with optional preventive medication
Trial: 29986085
Drug: Sodium oxybate
RxNorm normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium oxybate (Xyrem) oral solution, median dose 4.5 g per night at start, 6 g per night throughout study, in two equal doses.
Trial: 29986672
Drug: SMS reminder
RxNorm normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMS reminder (weekly)
Trial: 29986691
Drug: Bendamustine 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendamustine 75 mg/m²
Trial: 29986845
Drug: WelTel short-message
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WelTel short-message service (SMS) mHealth program; participants received mobile phones with unlimited texting and weekly bidirectional text messages for one year
Trial: 29986852
Drug: Lenalidomide at
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide at 10-, 15-, and 20-mg dose levels
Trial: 29986852
Drug: Lenalidomide maintenance
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide maintenance after salvage with high-dose methotrexate or focal irradiation
Trial: 29987139
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination tablet of dolutegravir (50 mg) and rilpivirine (25 mg)
Trial: 29987139
Drug: Separate tablets
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate tablets of dolutegravir and rilpivirine (reference treatment)
Trial: 29987139
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination tablet
Trial: 29987142
Drug: Ciprofloxacin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (10 to 15 mg/kg body weight every 12 h)
Trial: 29988503
Drug: Preventive Dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive Dexamethasone Treatment
Trial: 29988921
Drug: Bortezomib (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib (4 doses of 1.3 mg/m2 i.v.)
Trial: 29989854
Drug: Ado-trastuzumab emtansine
RxNorm normalized name: Ado-Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ado-trastuzumab emtansine at 3.6 mg/kg intravenously every 3 weeks until progression
Trial: 29991024
Drug: Sunitinib 37.5
RxNorm normalized name: sunitinib 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 37.5 mg once daily
Trial: 29991428
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I) for 8 weeks (n = 29)
Trial: 29992019
Drug: Glycated low-density
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycated low-density lipoprotein (g-LDL)
Trial: 29992039
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg a day taken orally
Trial: 29992080
Drug: IgM antibody
RxNorm normalized name: IgM antibody to ganglioside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgM antibody specific to pneumococcal surface protein A (PspA)
Trial: 29992080
Drug: IgM antibody
RxNorm normalized name: IgM antibody to ganglioside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgM antibody specific to an unencapsulated pneumococcal strain
Trial: 29992241
Drug: Pembrolizumab 10
RxNorm normalized name: pembrolizumab 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 10 mg/kg every 2 weeks until disease progression or intolerable toxicity for up to 24 months
Trial: 29992396
Drug: Cladribine Tablets
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cladribine Tablets (MAVENCLAD) with treatment postponement in year 2 based on ALC recovery
Trial: 29992396
Drug: Cladribine Tablets
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cladribine Tablets (MAVENCLAD) with treatment algorithm applied
Trial: 29992396
Drug: Cladribine Tablets
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cladribine Tablets (MAVENCLAD)
Trial: 29992599
Drug: Nurses' solution-focused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurses' solution-focused communication
Trial: 29996829
Drug: Individualized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized treatment plans
Trial: 29997136
Drug: Cyclosporine starting
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine starting dose of 5 mg/kg/day, decreasing to 3-3.5 mg/kg/day after 8 weeks
Trial: 29997898
Drug: Provider intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Provider intervention with patient-specific OA treatment recommendations
Trial: 30001986
Drug: Lirilumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lirilumab (3 mg/kg) as a single agent for lower-risk MDS patients
Trial: 30001986
Drug: Lirilumab in
RxNorm normalized name: Lirilumab
DrugBank: Lirilumab (DB11754)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lirilumab in combination with azacitidine (75 mg/m2) for higher-risk MDS patients
Trial: 30001986
Drug: Adverse events
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse events attributable to study drug
Trial: 30001987
Drug: Pazopanib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 800 mg/day plus cetuximab 400 mg/m
Trial: 30001987
Drug: Pazopanib 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 600 mg/day
Trial: 30001990
Drug: LTLD (liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LTLD (liposomal targeted drug delivery) followed by focused ultrasound exposure
Trial: 30002106
Drug: Chronic breathlessness
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic breathlessness treatment
Trial: 30002106
Drug: Chronic pain
RxNorm normalized name: Aspirin 81 mg ORAL TABLET [Chronic Pain/Fever Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic pain treatment
Trial: 30002113
Drug: NT-proBNP measurement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-proBNP measurement at enrollment (threshold of 1000 pg/mL)
Trial: 30002113
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of HeartLogic and NT-proBNP measurements
Trial: 30002864
Drug: Subcutaneous golimumab
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subcutaneous golimumab induction (200 mg initially and 100 mg at week 2) followed by maintenance (50 mg or 100 mg every 4 weeks until week 54)
Trial: 30003118
Drug: BAX 335,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAX 335, an AAV8-based hemophilia B gene therapy vector designed to express the FIX Padua variant.
Trial: 30003118
Drug: Phage display
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phage display technology to develop a Fab2 mini-antibody selectively binding to FIX Padua.
Trial: 30003579
Drug: Conventional analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional analysis (assumed treatment effect on mean only)
Trial: 30003996
Drug: Chemotherapy followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy followed by consolidative radiation therapy (CRT)
Trial: 30005644
Drug: Low-dose Neu2000
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Neu2000 (2.75 g)
Trial: 30005644
Drug: High-dose Neu2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Neu2000 (5.25 g)
Trial: 30006326
Drug: mHealth intervention
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mHealth intervention (weekly SMS messages including medical information, compliance importance, appointment reminders)
Trial: 30009214
Drug: Single sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single sequential microelectrode recordings
Trial: 30009213
Drug: DaxibotulinumtoxinA (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DaxibotulinumtoxinA (up to 200 U, single open-label intramuscular dose)
Trial: 30009275
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) consisting of 10 telephone-based sessions with an accompanying workbook
Trial: 30009275
Drug: Yoga consisting
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Yoga consisting of 10 weeks of group yoga classes (twice a week) modified for older adults
Trial: 30009815
Drug: Fructose (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructose (35 g) dissolved in 300 mL water
Trial: 30009815
Drug: Lactose (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose (50 g) dissolved in 300 mL water
Trial: 30009894
Drug: pEYS606 (non-viral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pEYS606 (non-viral gene therapy)
Trial: 30010630
Drug: aHLH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aHLH treatment
Trial: 30010891
Drug: Adalimumab treatment
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab treatment for at least 6 months
Trial: 30012192
Drug: Direct-acting antiviral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct-acting antiviral (DAA) treatment at the local tertiary institution (standard care arm)
Trial: 30012192
Drug: Direct-acting antiviral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct-acting antiviral (DAA) treatment at their primary healthcare services (intervention arm)
Trial: 30012528
Drug: Pembrolizumab 100
RxNorm normalized name: pembrolizumab 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 100 mg 3-weekly, starting 2 weeks before weekly adaptive bladder radiation therapy to a dose of 36 Gy in 6 fractions
Trial: 30012528
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of weekly radiation therapy with pembrolizumab
Trial: 30012756
Drug: Murepavadin (novel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Murepavadin (novel antipseudomonal antibiotic); single-dose administration; specific dosage not mentioned.
Trial: 30012767
Drug: Levofloxacin at
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin at doses of 11, 14, 17, or 20 mg/kg/day (minimum, 750 mg)
Trial: 30012788
Drug: m-RESIST solution
RxNorm normalized name: m-phenylenediamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m-RESIST solution (three mHealth tools: an app, wearable, and a web-based platform)
Trial: 30013511
Drug: E2 levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 levels between 14.0 and 17.4 pg/ml
Trial: 30013511
Drug: E2 levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 levels ≤10.5 pg/ml
Trial: 30013511
Drug: E2 levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 levels 10.6-13.9 pg/ml
Trial: 30013511
Drug: E2 levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 levels ≥17.5 pg/ml